Quest Partners LLC Cuts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Quest Partners LLC decreased its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 34.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,418 shares of the company’s stock after selling 1,794 shares during the period. Quest Partners LLC’s holdings in Kymera Therapeutics were worth $162,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in KYMR. Values First Advisors Inc. acquired a new position in shares of Kymera Therapeutics during the 3rd quarter worth $61,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after acquiring an additional 504 shares during the last quarter. Comerica Bank boosted its holdings in shares of Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after purchasing an additional 400 shares during the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in Kymera Therapeutics in the 2nd quarter valued at about $139,000. Finally, XTX Topco Ltd purchased a new stake in Kymera Therapeutics in the second quarter valued at approximately $201,000.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $46.86 on Friday. Kymera Therapeutics, Inc. has a 12-month low of $19.11 and a 12-month high of $53.27. The firm has a market capitalization of $3.03 billion, a P/E ratio of -20.03 and a beta of 2.21. The business has a 50 day simple moving average of $46.88 and a 200 day simple moving average of $42.11.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. During the same quarter last year, the business earned ($0.90) earnings per share. Kymera Therapeutics’s revenue was down 20.9% compared to the same quarter last year. Research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Morgan Stanley upped their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 6th. UBS Group lowered their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Guggenheim lifted their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Stephens started coverage on shares of Kymera Therapeutics in a report on Monday, November 18th. They issued an “overweight” rating and a $65.00 price objective on the stock. Finally, Leerink Partners restated an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Monday, September 9th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.13.

Insider Activity

In other news, Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 15.82% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.